Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Publisher Correction: Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Journal: Nature medicine
Published: June 24, 2026
Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.
Journal: Nature medicine
Published: April 22, 2026
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
Journal: Nature medicine
Published: December 12, 2025
Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes.
Journal: Diabetes, obesity & metabolism
Published: December 02, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
Journal: The New England journal of medicine
Published: June 23, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
Journal: Diabetes, obesity & metabolism
Published: September 23, 2024
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Journal: The New England journal of medicine
Published: June 23, 2023
Tirzepatide Once Weekly for the Treatment of Obesity.
Journal: The New England journal of medicine
Published: June 03, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026